Can polycythemia vera cause an elevated high‑sensitivity C‑reactive protein (hs‑CRP) level in a 54‑year‑old woman?

Can Polycythemia Vera Cause Elevated hs-CRP?

Yes, polycythemia vera (PV) can cause elevated high-sensitivity C-reactive protein (hs-CRP) levels, as PV is associated with a chronic inflammatory state that correlates with disease burden and thrombotic risk.

The Inflammatory Nature of PV

PV is fundamentally a myeloproliferative neoplasm driven by JAK2 mutations (present in >95% of cases) that creates a state of chronic inflammation 1, 2. The disease itself generates inflammatory markers independent of other cardiovascular risk factors.

Evidence for hs-CRP Elevation in PV

Research demonstrates that hs-CRP levels are significantly elevated in PV patients and correlate with several disease characteristics 1:

• hs-CRP levels correlate with the PV phenotype (higher in PV compared to essential thrombocythemia, P=0.006)
• Levels correlate with JAK2V617F allele burden >50% (P=0.003)
• Levels correlate with age and cardiovascular risk factors
• The highest hs-CRP tertile (>3 mg/L) was associated with higher major thrombosis rates (P=0.01) 1

A more recent study confirmed that hs-CRP levels in PV patients are independent of the mutational profile (unlike pentraxin-3, which correlates specifically with JAK2V617F homozygosity) 2. This means hs-CRP elevation reflects the overall inflammatory burden of the disease rather than specific genetic features.

Clinical Significance

Prognostic Value

High hs-CRP levels independently predict adverse outcomes in PV 2:

• Approximately 2-fold increased risk of hematological evolution
• Approximately 1.5-fold increased risk of death from any cause
• Increased risk of major thrombosis

These associations remained significant even after adjusting for age, gender, diagnosis, treatments, and JAK2V617F status 2.

Distinguishing from Other Causes

In your 54-year-old woman with PV and elevated hs-CRP, consider:

PV-related inflammation is the likely primary driver if:

• The elevation correlates with disease activity (leukocytosis, thrombocytosis, splenomegaly)
• JAK2V617F allele burden is high
• Other inflammatory conditions have been excluded

However, also evaluate for:

• Concurrent cardiovascular disease (hs-CRP is a general cardiovascular risk marker) 3
• Infection or other inflammatory conditions
• Thrombotic complications (which are more common in PV and themselves elevate hs-CRP)

Clinical Implications

While hs-CRP is elevated in PV and has prognostic value, current guidelines do not recommend routine hs-CRP monitoring or using it to guide treatment decisions 4, 5. The management of PV remains focused on:

• Phlebotomy to maintain hematocrit <45% 6, 7
• Low-dose aspirin (81-100 mg daily) unless contraindicated
• Cytoreductive therapy (hydroxyurea or pegylated interferon) for high-risk patients (age >60 years or prior thrombosis history) 4, 5, 6, 7

The elevated hs-CRP in your patient should prompt:

1. Aggressive cardiovascular risk factor management
2. Ensuring adequate disease control with appropriate cytoreduction if high-risk
3. Maintaining hematocrit <45% with phlebotomy
4. Consideration of the patient's overall thrombotic risk profile

The hs-CRP elevation is a marker of the inflammatory burden of PV itself and reinforces the need for optimal disease control rather than representing a separate treatment target.